A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

To join this study, you must be at least 18 years old and have been diagnosed with Extensive Stage Small Cell Lung Cancer (ES-SCLC). Your cancer should be 'measurable,' meaning doctors can see and track it, and you shouldn't have had previous treatments for ES-SCLC, apart from possibly your very first round of chemotherapy. Your general health, as assessed by a doctor, should be good enough to take part, and you should be expected to live for at least six more months.

There are also some reasons why you might not be able to join. For example, if you've already had certain types of anti-cancer treatments that affect your immune system, or if you have serious ongoing infections like tuberculosis, hepatitis B, or hepatitis C. Also, if you have certain heart problems, severe autoimmune diseases, or allergies to any of the study medications, you wouldn't be able to participate. You also shouldn't be involved in another medical study at the same time.

If you decide to take part, the study will involve several stages. First, there's a screening period of up to 28 days to check if the treatment is right for you, including a special scan to look at your cancer. Then, you'll enter the treatment period, which has two parts: an 'Induction' phase followed by a 'Maintenance' phase. During the early part of the study, different groups of participants will receive different doses of the new treatment to find the safest level. Once a safe dose is found, about 140 participants will be randomly assigned to either receive the new combination treatment or the current standard treatment. After the treatment period, there will be a follow-up period where doctors will continue to monitor your health. The total duration of your participation will depend on the stage of the study and how your body responds to the treatment.